کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10298124 | 539139 | 2013 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension
ترجمه فارسی عنوان
اثر لوازیدون بر عملکرد عصبی شناختی در بیماران مبتلا به اسکیزوفرنی: یک مطالعه کوتاه مدت دارونما و کنترل فعال و پس از آن 6 ماه طولانی مدت دوسوکور
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
لوازیدون، عملکرد عصبی شناختی، ظرفیت کاری، جنون جوانی،
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
روانپزشکی بیولوژیکی
چکیده انگلیسی
This double-blind study evaluated change in cognitive performance and functional capacity in lurasidone and quetiapine XR-treated schizophrenia patients over a 6-week, placebo-controlled study, followed by a 6-month, double-blind extension. Cognitive performance and functional capacity were assessed with the CogState computerized cognitive battery and the UPSA-B. Analyses were conducted for all subjects, as well as the subsample whose test scores met prespecified validity criteria. No statistically significant differences were found for change in the composite neurocognitive score for lurasidone (80Â mg/day and 160Â mg/day) groups, quetiapine XR and placebo in the full sample at week 6. For the evaluable sample (N=267), lurasidone 160Â mg was superior to both placebo and quetiapine on the neurocognitive composite, while lurasidone 80Â mg, quetiapine XR, and placebo did not differ. UPSA-B scores were superior to placebo at 6 weeks for all treatments. In the double-blind extension study, analysis of the full sample showed significantly better cognitive performance in the lurasidone (40-160Â mg) group compared to the quetiapine XR (200-800Â mg) group at both 3 and 6 months. Cognitive and UPSA-B total scores were significantly correlated at baseline and for change over time. This is the first study to date where the investigational treatment was superior to placebo on both cognitive assessments and a functional coprimary measure at 6 weeks, as well as demonstrated superiority to an active comparator on cognitive assessments at 6 weeks and at 6 months of extension study treatment. These findings require replication, but are not due to practice effects, because of the placebo and active controls.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Neuropsychopharmacology - Volume 23, Issue 11, November 2013, Pages 1373-1382
Journal: European Neuropsychopharmacology - Volume 23, Issue 11, November 2013, Pages 1373-1382
نویسندگان
Philip D. Harvey, Cynthia O. Siu, Jay Hsu, Josephine Cucchiaro, Paul Maruff, Antony Loebel,